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We present an unconventional approach to antiviral drug discovery,
which is used to identify potent small molecules against rabies virus.
First, we conceptualized viral capsid assembly as occurring via a host-
catalyzed biochemical pathway, in contrast to the classical view of
capsid formation by self-assembly. This suggested opportunities for
antiviral intervention by targeting previously unappreciated catalytic
host proteins, which were pursued. Second, we hypothesized these
host proteins to be components of heterogeneous, labile, and
dynamic multi-subunit assembly machines, not easily isolated by
specific target protein-focused methods. This suggested the need to
identify active compoundsbefore knowing thepreciseprotein target.
A cell-free translation-based smallmolecule screenwas established to
recreate the hypothesized interactions involving newly synthesized
capsid proteins as host assembly machine substrates. Hits from the
screen were validated by efficacy against infectious rabies virus in
mammalian cell culture. Used as affinity ligands, advanced analogs
were shown to bind a set of proteins that effectively reconstituted
drug sensitivity in the cell-free screen and included a small but
discrete subfraction of cellular ATP-binding cassette family E1
(ABCE1), a host protein previously found essential for HIV capsid
formation. Taken together, these studies advance an alternate view
of capsid formation (as a host-catalyzed biochemical pathway),
a different paradigm for drug discovery (whole pathway screening
without knowledge of the target), and suggest the existence of labile
assembly machines that can be rendered accessible as next-genera-
tion drug targets by the means described.
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Rabies virus (RABV) poses a worthwhile challenge for anti-viral drug discovery (1). Despite the existence of an effective
vaccine, more than 50,000 humans die of rabies annually
worldwide (2). [In fact, this estimate is likely very low, because
many human rabies cases occur in areas where incidence is
underreported by up to 100-fold (2).] Because vaccine efficacy
for postexposure prophylaxis is strictly time limited, millions
more are at risk, even in areas with adequate health care
resources (3). Upon onset of symptoms, the disease has a nearly
100% case fatality rate (4), making it arguably the most deadly
viral disease of humans, and no effective small-molecule thera-
peutic has been found previously. A drug that is inexpensive to
produce, that can be stored at room temperature, thereby fa-
cilitating distribution and access, and that demonstrates efficacy
during the symptomatic stage of the disease would address this
ancient and significant public health need.
The lifecycles of all viruses involve variations on a common
theme. A viral particle must release its genome inside a host cell,
replicate its genetic information, express encoded proteins, and
assemble capsids (the protein shell that protects the viral ge-
nome) before completing formation/maturation and release of
new viral particles. Capsid assembly is a highly efficient process,
often occurring in organized structures that have been described
as “viral factories” (5). Although catalytic roles for host proteins
are recognized for most steps in the viral lifecycle, capsid assembly
still is viewed commonly as a spontaneous, thermodynamically
driven process termed “self-assembly” (e.g., refs. 6 and 7).
However, studies in three diverse viral families, HIV (8–13),
hepatitis B virus (14), and hepatitis C virus (15, 16), suggest a very
different path to capsid formation. In this alternative view,
capsid assembly occurs via discrete assembly intermediates within
a biochemical pathway involving energy-dependent and host
factor-dependent steps. Based on these studies, we hypothesized
that analogous events occurred in RABV capsid assembly and
that viewing capsid assembly as a concerted biochemical process
including critical host protein-catalyzed steps would prove pro-
ductive when applied to drug discovery. Likely participants in such
steps would be protein machines involved in other assembly
events for the host that are commandeered upon viral infection,
manipulated, and possibly modified to meet the needs of the virus
for capsid assembly. Host assembly machines that have been op-
timized for the virus rather than for the host (e.g., by viral ma-
nipulation of host-signaling pathways) are promising antiviral
targets that likely can be blocked without substantial toxicity; al-
though they are composed of host proteins, their loss should not
impair a host function, only propagation of the virus. Perhaps
previous efforts to develop anti-capsid therapeutics have been
disappointing precisely because they did not target the hypothe-
sized host enzymes of capsid formation but rather attempted to
block capsid protein interactions directly (17, 18).
The identification of druggable targets remains a substantial
hurdle facing contemporary small-molecule drug discovery (19).
[The term “druggable targets” is defined by Hopkins et al. (19) as
targets that are able to bind compounds with the properties of
a commercially viable drug (i.e., compounds that are orally
bioavailable and conform to Lipinski’s rule of five) (20).] Con-
ventional targets soon will be exhausted, and the likely highly
unconventional targets of the future remain elusive to prevailing
approaches (20). We believe that many highly druggable targets,
including the assembly machines hypothesized here, have been
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missed because conventional drug discovery typically starts with
target identification. However, if the target is a labile multi-
protein complex (MPC) that defies conventional purification,
and if such MPCs are highly heterogeneous with small, discrete,
and nonoverlapping subsets of the component proteins serving as
parts of different assembly machines, then unorthodox approaches
would be necessary to pursue such targets.
During the last decade, there has been a growing appreciation
of the abundance and diversity of MPCs within the cell (21–23).
MPCs represent the core of the protein–protein interaction
(PPI) networks responsible for a multitude of biological functions
(23, 24). Effective therapeutic modulation of MPC PPIs would
be powerful (25, 26), but a history of unsuccessful attempts has
led to the widespread opinion that such targets are not druggable
(19). We hypothesize that these setbacks can be attributed to the
limitations imposed by both traditional drugs and traditional
approaches to drug discovery and that a different approach
might be successful. First, most existing small-molecule drugs
achieve their activity by competing directly with an endogenous
molecule for a functional binding site (19). This type of mech-
anism is not easily applied to MPCs, which often involve large
binding surfaces, weak affinities, transient interactions, and dis-
ordered protein regions (26, 27). Biological systems generally
modulate PPIs through allostery rather than direct inhibition,
indicating that binding an allosteric site is much more likely to be
an effective mechanism for drug action against MPC targets (26).
Second, the predominant approach to drug discovery involves
identifying a specific target before finding a lead compound,
thereby limiting discovery to targets of sufficient stability for
conventional purification. Labile complexes of loosely associated
proteins that are unstable (at least once the cell is disrupted)
therefore are not readily amenable to standard purification tech-
niques. Thus, perhaps the biggest obstacle to identifying drugs that
target MPCs is that the MPCs themselves can be missed by target-
based drug-discovery programs.
As an alternative to a target-based program, we propose
functional reconstitution of critical PPIs involved in the capsid-
assembly pathway following de novo synthesis of the capsid
protein as a putative assembly substrate. If even a portion of the
capsid-assembly pathway involving newly synthesized capsid
proteins has been reconstituted, it can be converted readily into
a screen for the identification of small molecules that block any
earlier step in the pathway—without knowledge of the target.
Hits from this screen can be validated by their activity against
infectious virus in cell culture and then subjected to optimization
of the structure–activity relationship (SAR) to establish quickly
whether their targets are truly druggable. The successfully ad-
vanced compounds themselves then can be used as affinity
ligands to fractionate the starting extract (before translation of
the viral capsid protein mRNA) far more rapidly than could be
done without the drug-based affinity ligand. The protein(s)
bound to the affinity ligand that are eluted specifically by free
compound would comprise the drug target. The identity of the
target can be confirmed by comparing assembly reaction prod-
ucts from starting, fractionated, target-depleted, and target-
reconstituted extracts. Thus, a classical cell biological approach,
de novo cell-free protein synthesis (CFPS) (28), is used effec-
tively to turn conventional drug discovery on its head: to find the
compound first by using a whole pathway screen and to identify
the target later by advanced analog affinity chromatography, val-
idated by functional reconstitution of the hypothesized assembly
pathway. Here we successfully demonstrate this approach for
RABV and show that the drug target has the hypothesized
unconventional properties.
Results and Discussion
RABV Assembly Pathway. RABV has a nonsegmented negative-
strand RNA genome that codes for five proteins: the nucleo-
protein (N), the phosphoprotein (P), the matrix protein (M), the
glycoprotein (G), and the large protein (L). Together, L and P
comprise the viral polymerase. N encapsidates the RNA genome
in a tight helical RNase-resistant ribonucleoprotein (RNP)
capsid (29). P has been shown to associate with N (30, 31) before
RNP capsid assembly at a P:N ratio of 2:1, in contrast to the 1:2
ratio found in the completed capsid (32–34). Formation of the
RNP capsid is followed by virion assembly and budding, models
for which can be found in the literature (29). These models
emphasize the multiple roles of M, which include condensing the
RNP complex and coordinating budding by associating with both
the capsid and budding sites on the cell membrane designated by
microdomains of transmembrane G. Because of the complexity
Fig. 1. Cartoon of the proposed RABV capsid-assembly pathway, based on
our findings and data in the literature cited. (A) Nascent RABV N. (B)
P associates with unassembled N monomers (30–34). (C) One or more host
multiprotein complex is hypothesized to facilitate capsid assembly. (D) The
capsid-assembly pathway involves energy-dependent steps. (E) Completed
capsid. Interference with this pathway by energy depletion, host factor de-
pletion, or small-molecule activity can block progression along the pathway
or lead to off-pathway interactions and the formation of aberrant capsids.
Fig. 2. (A) Autoradiogram of 35S-radiolabeled CFPS translation products of the N, M, and P genes of RABV, individually and when coexpressed, as analyzed
by SDS/PAGE. Major bands correspond to the expected sizes of the RABV N, M, and P proteins. (B) Sucrose gradient quantification of RABV N expression in
a CFPS reaction programmed with RABV N, M, and P mRNA under synthesis (26 °C for 1 h) (Left) and subsequent assembly conditions (26 °C for 1 h→ 34 °C for
2 h) (Right). Note the progression of N from being predominantly at the top of the gradient after synthesis, diminishing in material at the top of the gradient,
and increasing in the peak in fraction 6 after incubation (Right, downward pointing arrow).
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of M and P interactions with N, all three viral genes were
coexpressed by CFPS. For the purposes of the present study, we
simply need (i) to hypothesize that such interactions occur (Fig.
1); (ii) to show that those interactions are broadly resolvable
into two steps, one predominantly for synthesis of the RABV
proteins and another to enhance assembly into large structures
(Fig. 2); (iii) to convert those reactions into a whole-pathway
screen; and (iv) to make testable predictions regarding validation
of hits from that screen against infectious RABV in cell culture
(see below).
RABV CFPS Drug Screen. To use CFPS programmed with RABV
gene products for the identification of small molecules that block
or alter progression through the hypothesized assembly pathway,
we first demonstrated that synthesis of RABV N, P, and M
proteins, individually or together, in a wheat germ (WG) CFPS
at 26 °C for 1 h results in protein products of the correct size
(Fig. 2A). When the translation products were analyzed by su-
crose step gradients, they localized predominantly to the top of
the gradients (Fig. 2B, Left). Upon subsequent incubation at 34 °C
for 2 h, followed by the same gradient analysis, RABV N was
converted to higher molecular weight complexes (Fig. 2B, Right).
By analogy to previous studies of capsid protein expression by
CFPS (12, 14, 35–37), we hypothesized that the high molecular
weight RABV complexes containing N represented the culmi-
nation of myriad PPIs in a RABV capsid-assembly pathway.
We then devised a fluorescent plate assay to monitor the
formation of multimeric N-containing structures (Fig. 3). RABV
N, M, P, and eGFP mRNAs were translated by CFPS in 384-well
format in the absence or presence of small molecules under the
conditions shown in Fig. 2B to achieve both synthesis and pu-
tative RABV assembly. Coexpression of eGFP, an unrelated
protein that is inert in the capsid-assembly process, serves to
measure effects of individual small molecules on protein syn-
Fig. 3. Diagram of the CFPS whole-pathway plate screen. (A) CFPS system consisting of cellular extract, RABV N, M, and P mRNAs, eGFP mRNA, amino acids,
and an energy-regenerating system. (B) Hypothesized synthesis and assembly of RABV capsid proteins occurring during the sequential incubation steps
described in Fig. 2. (C) CFPS translation products transferred to a capture plate previously coated with anti-RABV N affinity-purified antibody. (D) RABV N
bound to the capture plate is decorated with biotinylated secondary antibody, which is used to generate a fluorescent readout. (E) Drug treatment that
blocks the formation of large N multimers or that results in the formation of aberrant structures that mask epitopes results in inhibition of fluorescence. To
ensure diminution in fluorescence is not caused by inhibition of protein synthesis, eGFP is cotranslated with RABV proteins, and the extent of eGFP fluo-
rescence is monitored before transfer to the capture plate. Compounds whose inhibition of N-derived fluorescence is comparable to the inhibition of eGFP
fluorescence are likely to be false positives.
Fig. 4. (A) Detection of active compound PAV-612 compared with inactive
compound PAV-637 by CFPS plate screen. Assembly is measured in relative
fluorescent units (RFU). Error bars represent SD of triplicates. (B) Fluorescence
of cotranslated eGFP, demonstrating that the observed drug effect is not in-
hibition of protein synthesis. (C) PAV-612 activity corroborated by 50% tissue
culture infective dose (TCID50) assessment in Vero cells 40 h after infection.














thesis. Diminution of eGFP fluorescence allows us to distinguish
hits that merely inhibit protein synthesis from those that block
capsid assembly. Products then were captured on a second 384-well
plate coated with affinity-purified antibody to RABV N (anti-N),
and decorated with biotinylated anti-N. The bound biotinylated
antibody was used to generate a fluorescent readout. When a
monomer of N is captured, its single epitope is occupied, and
there are no exposed epitopes to bind biotinylated antibody.
However, either completed capsids or even assembly inter-
mediates, comprising many copies of N, should expose epitopes
in excess of that used for capture and should give a robust
fluorescent signal. If a small molecule present in the synthesis
plate disrupts any step in the assembly process, epitope exposure
is likely to change, and therefore the fluorescent signal should
change, in a dose-dependent fashion. A portion of the Prosetta
compound collection, comprising small molecules conforming to
Lipinski’s rule of five (38), was screened, and compounds showing
selective dose-dependent change of N fluorescence were iden-
tified as hits.
Compound Advancement. We identified a small set of modestly
active compounds in the CFPS screen and assessed these in Vero
cells against a strain of “street rabies” isolated from a rabid gray
fox. Fig. 4 shows the data from an active compound, PAV-612,
compared with an inactive compound, PAV-637. A set of ana-
logs then was synthesized and assessed in both the CFPS screen
(Fig. 5A) and against infectious RABV in cell culture (Fig. 5B).
These analogs demonstrate a robust SAR for efficacy, suggesting
an excellent starting point for anti-RABV drug discovery. The
extent of activity on the screen corresponds roughly to the degree
of activity observed against infectious RABV in cell culture.
These results validate our CFPS-based screen, support our
working hypotheses on capsid assembly, and highlight the value
of a whole-pathway screen as outlined above.
One analog, PAV-866 (Fig. 6A), was chosen for further study.
PAV-866 has an EC50 against infectious RABV in Vero cell
culture of ∼15–30 nM (Fig. 6B) and eliminates all RABV in-
fectivity (>9 logs) in the low μM range. When assessed for toxicity
in Vero cells, this compound was found to have a 50% cytotoxic
concentration (CC50) of ∼2.5–10 μM. Thus, the selectivity index
(SI) or CC50/EC50 of this compound was ∼100. Although other
compounds in this chemical series (such as PAV-112 and PAV-
865) were more potent than PAV-866 against infectious RABV
in cells, they also were more toxic and therefore had a lower SI.
Time of Drug Action. If these compounds act on host factors that
play a catalytic role in viral capsid assembly, their efficacy should
depend on the addition of the compound within the hypothe-
sized time frame of action, i.e., during capsid protein synthesis
and assembly. In cell culture we compared the effect of various
times of PAV-866 addition (1–12 h after infection) on the in-
fectivity of the medium harvested 72 h after infection. If, con-
trary to our hypothesis, the compounds acted directly on the
progeny virus, infectivity would be eliminated equally regardless
of the time at which the compound was added during the first
12 h of the 72-h time course, because the compound would still
have the opportunity to act on the virus in the medium before
Fig. 5. (A) Analogs to PAV-612 demonstrating a robust SAR on the CFPS
plate screen. Error bars represent SD of triplicates. (B) Activity of PAV-612
analogs against infectious RABV in Vero cells as assessed by measurement of
focus-forming units per milliliter of the medium (Upper) and by DFA assay of
the cells in the primary infection plate (Lower).
Fig. 6. (A) Structure PAV-866, a small molecule (FW = 432). (B) PAV-866 has
potent activity against RABV in cell culture in the low nanomolar range.
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harvest. As shown in Fig. 7, the efficacy of PAV-866 diminishes
strikingly when it is added at times beyond 6 h postinfection. This
result is consistent with compound action on intracellular targets
within the proposed host-catalyzed capsid-assembly pathway.
Target Isolation, Depletion, and Reconstitution. If, as proposed,
these compounds target a labile assembly machine that is an
MPC, it may be possible to take advantage of the high affinity of
PAV-866 for the functional target to isolate the hypothesized
MPC by affinity chromatography, a protein-separation method
that exploits the specific interaction between an immobilized
ligand and proteins of interest (39). PAV-866 was coupled to
a resin (termed column 124) and used as an affinity ligand for
column chromatography. A column of blocked resin without
compound (column 74) served as a negative control for binding
specificity. The starting WG extract (before its use for CFPS
expression of RABV proteins) was applied to the columns.
Columns were washed with 50 bed volumes of buffer and then
were incubated with free PAV-866 to elute proteins bound
specifically to the ligand. SDS/PAGE and silver-stain analysis of
the eluate revealed a striking set of proteins that bound specif-
ically to column 124 and not to column 74 and that were eluted
with free compound (Fig. 8A). Affinity chromatography of
mammalian brain postmitochondrial supernatant (PMiS) pro-
duced a pattern of proteins similar to that seen in the eluate from
WG extract that is used for CFPS (Fig. 8B). Concurrence of the
set of binding proteins from both plant and brain extracts sug-
gests a conserved set of PPIs and is remarkable, given RABV
neurotropism. RABV capsids generated by Triton X-100 treat-
ment of irradiated authentic RABV showed no specific binding
to column 124, reinforcing our earlier conclusion that the drug
target is a host cellular protein rather than a viral protein (Fig. 9).
To verify that the factors that bound column 124 indeed in-
cluded the drug target, we collected the WG extract column
flow-through depleted of PAV-866–resin conjugate-bound pro-
teins. CFPS reactions carried out in depleted extract lack the
dose-dependent drug effects seen in the plate screen using the
starting extract (Fig. 10 A and B), indicating that the target was
missing from the 124 column flow-through. However, when the
depleted extract is reconstituted with column 124 eluate (ex-
haustively dialyzed to remove both free and bound drug), the
dose-dependent drug effect is restored fully (Fig. 10C), con-
firming that the eluate contains the drug target.
Drug Target Composition. ATP-binding cassette family E1 (ABCE1),
a host protein formerly known as “HP68” (40) and “RNase L in-
hibitor” (41), has been implicated in various activities including
ribosome recycling (42–46) and HIV capsid assembly (8–11, 13, 40).
By Western blotting with an affinity-purified antibody raised
to a C-terminal epitope of ABCE1, we show the presence of
ABCE1 in both WG and PMiS column 124 eluates (Fig. 8C).
Starting extracts that were analyzed by glycerol gradient ul-
tracentrifugation and then Western blotted for ABCE1 displayed
an extremely heterogeneous distribution across the gradient
(shown for PMiS in Fig. 11, Top) When individual gradient
fractions were applied to drug columns, only a very small portion
of total ABCE1, belonging to a single discrete subfraction mi-
grating predominantly in glycerol gradient fraction 3 and ac-
counting for ∼1–5% of total cellular ABCE1, is bound to the
column (Fig. 11, Middle). This result suggests that only a small
subset of the total ABCE1 present in the cell is incorporated
into the MPC relevant for the step in RABV capsid formation
targeted by PAV-866. These data are consistent with the hy-
pothesized heterogeneity and unconventional properties of the
MPC comprising the drug target.
It is remarkable that only a tiny subfraction of total host
ABCE1 was found to be competent to bind the PAV-866 resin
conjugate. Because each gradient fraction was assessed in-
dependently for drug binding, the failure of the great majority
of ABCE1 to bind suggests substantial heterogeneity of ABCE1,
rendering conventional proteomic and molecular biological
methods (e.g., siRNA knockdown) unlikely to be able to distin-
guish the minor subfraction likely to represent the true PAV-866
target. Hence, without the unconventional approach and un-
orthodox hypotheses presented here, the target MPCs and the
drugs that block them likely would not have been identified.
Conclusions
Previous studies used CFPS to achieve faithful assembly of
capsids for multiple families of viruses (12, 14, 16). We therefore
approached antiviral drug discovery from the perspective of the
capsid protein being the substrate for a host-catalyzed bio-
chemical pathway driven by an MPC. We further hypothesized
the reasons for the failure of previous studies either to develop
effective anti-capsid compounds or to detect roles for catalytic
host-derived capsid-assembly machines and established an ap-
proach by which these obstacles might be circumvented and the
Fig. 7. Effect of time of addition on PAV-866 action against RABV in cell
culture. Drug was added at various times ranging from 1 to 12 h after in-
fection, and efficacy was assessed by determining the number of focus-
forming units per milliliter of medium 72 h after infection.
Fig. 8. Silver-stained SDS/PAGE showing the banding pattern of total ex-
tract, PAV-866 eluates from column 74, and PAV-866 eluates from column
124 for (A) WG extract and (B) PMiS. (C) Western blot of the 68-kDa ABCE1
protein from WG extract column 124 PAV-866 eluates (Left) and PMiS col-
umn 124 PAV-866 eluates (Right).














hypothesized MPC-assembly machines identified. We used
RABV as a test case. A cell-free de novo synthesis screen was
established and used to identify hits whose efficacy was validated
against infectious RABV in mammalian cell culture. The active
compounds were subjected to SAR optimization, and an advanced
analog coupled to resin was used for affinity chromatography to
identify the targets. A set of proteins, including ABCE1, a host
protein previously shown to be essential for HIV capsid forma-
tion, was identified by free drug elution from the drug resins and
was shown to include the drug target collectively by functional
reconstitution of drug sensitivity in the same CFPS screen by
which the active compound was identified in the first place. It
should be noted that these studies have not established whether
ABCE1 is the direct (nearest neighbor) PAV-866–binding protein.
It also is possible that ABCE1 is involved in multiple steps or that
different subsets of ABCE1 play different roles in the capsid-
assembly process. Further studies with the system, tools, and
reagents described here should clarify these issues.
The work presented here was predicated on the hypothesis of
host catalysis (47) of capsid formation by labile MPCs and was
designed to overcome pitfalls of conventional antiviral drug
discovery. When applied to RABV, a virus for which no antiviral
therapy currently exists, this approach successfully identified
compounds of striking antiviral potency and excellent thera-
peutic index in cell culture, whose target appears to be a labile
host MPC comprising highly heterogeneous protein components.
If host protein functional heterogeneity in assembly machines is
as massive as implied by this study, and if, as suggested, such
MPCs are viable drug targets, the approach taken here to identify
antiviral compounds may have broader applications to next-
generation drug discovery not limited to antiviral therapeutics.
Materials and Methods
Materials were purchased from Sigma Chemical Co. or Thermo Fisher, unless
otherwise noted. Affinity-purified antibodies to RABV N and ABCE1 are
available from www.prosetta.co.in.
Cell-Free Transcription and Translation. Coding regions of interest (RABV N, P,
and M) were engineered behind the SP6 bacteriophage promoter and the
Xenopus globin 5′ UTR. DNA was amplified by PCR and then transcribed in
vitro to generate mRNA encoding each full-length protein. Translations
were carried out in the WG CFPS system either supplemented with 35S amino
acid or with all 20 nonradiolabeled amino acids, as previously described (12,
14) but at reduced concentrations of WG extract. Samples in Fig. 2 were
radiolabeled, allowing their direct detection by SDS/PAGE and autoradiograph;
those used for the CFPS plate screen (Figs. 4 and 5) were not radiolabeled and
were detected by antibody capture and detection as described in Fig. 3.
Sucrose Step Gradients. Sucrose step gradients were performed as previously
described (12, 14) and were analyzed by SDS/PAGE, autoradiography, and
quantification of RABV N band density.
Moderate-Throughput Small-Molecule Screening.Moderate-throughput small-
molecule screeningwas carriedout in a 384-well format by translation of eGFP
and RABV N, P, and M mRNA in the presence of small molecules from the
Prosetta compound collection. Reactionswere runat26 °C for 1h for synthesis,
followed by assembly at 34 °C for 2 h. eGFPfluorescent readoutwasmeasured
at 488/515 nm (excitation/emission). Products were captured on a second 384-
well plate precoatedwith affinity-purified antibody. Plates werewashedwith
PBS containing 1% Triton X-100, decorated with biotinylated affinity-puri-
fied antibody, washed, detected by NeutrAvidin HRP, washed again, and
then incubated with a fluorogenic HRP substrate Quanta Blue for 1 h. Fluo-
rescent readout was measured at 330/425 nm (excitation/emission). Relevant
reagents were obtained from Pierce Protein Research Products.
Antibody Generation. A peptide epitope of RABV N exposed on the surface of
RABV capsids (48), CFFRDEKELQEYEAAELTKTVDALADD, with N-terminal
acetylation and C-terminal amidation to mimic its internal position in the
RABV N sequence, was chosen for coupling to carrier and immunization of
rabbits, and polyclonal rabbit antibodies were generated as described (49).
Bleeds were screened by Western blot and immunoprecipitation of radio-
labeled RABV N products. High-titer sera were pooled and affinity purified
as described.
Cells and Virus. Street RABV (TxFX A11-1198), associated with enzootics in
carnivores throughout the southwest United States, was derived from the
salivary glands of a rabid gray fox (Urocyon cinereoargenteus). Mouse
neuroblastoma (MNA) cells were propagated in Eagle minimal essential
medium supplemented with 10% FBS. In multiple wells of a 96-well plate,
MNA cells (except control cells) were infected with RABV at a multiplicity of
infection (MOI) of 0.1 per cell and were incubated at 37 °C for 48 h in the
presence of MEM supplemented with 10% FCS. Then 100 μL of supernatant
was removed from each well and replaced with an antiviral compound at
described concentrations. Cells were incubated for an additional 48 h.
RABV Infectivity Titration. After incubation, 100 μL of supernatant was
removed and titrated on MNA. Microtiter plates were washed twice in PBS
Fig. 9. Western blot of authentic RABV capsids’ binding affinity to columns
of resins 124 (PAV-866 conjugate) and 74 (negative control). Lane 1 shows an
aliquot of flow-through that did not bind to column 124. Lanes 2–5 show
a serial dilution of authentic capsid starting material, demonstrating the
limits of detectability by Western blot (∼0.1% of input). Lanes 6–9 and 10–13
are first, second, and overnight eluates and a urea wash from columns 124
and 74, respectively. No specific binding to 124 resin columns (lanes 6–9)
compared with control 74 resin columns (lanes 10–13) is detectable.
Fig. 10. Plate assay profiles of CFPS reactions in the presence of a titration
of a PAV-866 analog carried out in (A) starting, (B) depleted, and (C)
reconstituted cellular extracts. Reactions carried out in starting extracts show
familiar dose–response curves, reactions carried out in depleted extracts
show no drug effects, and reactions carried out in reconstituted extracts
show a full restoration of dose-dependent drug effect. Error bars represent
SD of triplicates. The presence of full RFUs but no drug effect in the absence
of target (upon expression in the depleted extract, B) and restoration of
drug effect upon target protein reconstitution by the addition of dialyzed
free drug eluate (upon expression in reconstituted extract, C) is consistent
with the hypothesis that the plate screen is not a simple readout of multi-
merization. Loss of RFUs upon drug treatment in the presence of target is
likely due to formation of aberrant structures in which the relevant epitopes
are masked. It is not surprising that the consequence of target depletion
itself is different from the consequence of treatment with the drug used as
an affinity ligand to achieve target depletion. In the former instance, one of
the capsid-assembly factors is missing; in the latter instance, the assembly
factor is present but nonfunctional (because of drug action), perhaps con-
ferring the equivalent of a dominant negative phenotype.
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(pH 7.2–7.4) and fixed with 80% acetone at −20 °C. RABV antigens were
detected by direct fluorescent antibody staining using FITC-labeled mono-
clonal antibody conjugate (Fujirebio Diagnostics, Inc.). Titers for infectious
virus released into the supernatant were calculated by the Reed and Muench
method. The BSR cells [a clone of baby hamster kidney (BHK) cells] were
grown in DMEM supplemented with 10% FBS (Atlanta Biologicals) at 37 °C
in a 5% CO2 incubator. The RABV ERA strain was obtained from The
American Type Culture Collection and maintained at The Centers for Disease
Control and Prevention in Atlanta. For virus titration and antiviral com-
pound treatment, the confluent BSR cells in T75 flasks were split and seeded
to a 24-well plate (Fisher Scientific). After 24 h incubation, the confluent BSR
cells in the plate were infected with 1 MOI of RABV ERA either before or
after treatment with the antiviral compound at the indicated time course.
The virus titer in the treated cell supernatants was calculated in focus-
forming units (ffu) per milliliter. In brief, 20 μL of cell supernatants mixed
with 180 μL of freshly prepared BSR cell suspension was seeded into a Lab-
Tek Chamber Slide (Fisher Scientific). A serial 10-fold dilution of the virus–
cell supernatants was made with similar BSR cell suspensions in the same
slide. The cells were incubated at 37 °C in a 5% CO2 incubator for 24 h before
titration using the direct fluorescent antigen (DFA) assay. A standard DFA
protocol (www.cdc.gov/rabies/pdf/rabiesdfaspv2.pdf) was followed for virus
titration for the effect of antiviral compound treatment against the original
cells grown in the 24-well plate.
Affinity Chromatography. Compound resin conjugate (50–100 μL) was equil-
ibrated in a buffer containing 50 mM Hepes or triethanolamine (pH 7.5),
0.35% Triton X-100, and 0.2 mM thioglycolate (pH 7.5). Up to 50 uL of su-
crose step gradient fraction was applied. The column was clamped and in-
cubated at 4 °C for 1 h and then washed with 100 bed volumes of the same
buffer. One bed volume of free compound at 200 μg/mL (approaching its
maximum solubility in water) was added, the column was clamped for 1 h,
and three serial eluates were collected. The column then was washed ex-
tensively, clamped for 1 h in 8 M urea, washed further, and equilibrated in
isopropanol for storage. Column eluates were subjected to exhaustive di-
alysis to remove both free and bound compound.
Authentic Irradiated RABV.Authentic irradiated RABVwas treated with Triton
X-100 to solubilize the envelope and release the capsid and then was applied
to columns of resins 124 (PAV-866 conjugate) and 74 (negative control). Later,
columns were incubated with free compound to elute bound proteins and
were washed with urea. Western blots of authentic capsids were probed
with anti-N.
Glycerol Gradients. Glycerol gradients were poured using a linear gradient
former from 5–35% glycerol in 10 mM triethanolamine (pH 7.6), 10 mM
NaCl, 1 mM magnesium acetate, and 0.2 mM EDTA. Samples up to 200 μL
were loaded onto chilled gradients and centrifuged in a TL-100 Beckman
centrifuge using a TLS-55 swinging bucket rotor at 50,000 rpm for 55 min
with slow acceleration and deceleration. Gradients were fractionated into
eleven 200-μL aliquots and analyzed by SDS/PAGE.
SDS/PAGE. SDS/PAGE was carried out as previously described (12, 14).
Western Blotting. For Western blotting, SDS/PAGE gels were transferred in
Towbin buffer to polyvinylidene fluoride membrane, blocked in 1% BSA,
incubated for 1 h at room temperature in a 1:1,000 dilution of 100 μg/mL
affinity-purified primary IgG, washed three times in PBS with 0.1% Tween-
20, and incubated for 1 h in a 1:5,000 dilution of secondary anti-rabbit an-
tibody coupled to alkaline phosphatase. This incubation was followed by
washing to various degrees of stringency by elevation of salt, a Tris-buffered
saline wash, and incubation in developer solution prepared from 100 μL of
7.5 mg/mL 5-Bromo-4-chloro-3-indolyl phosphate dissolved in 60% dimethyl
formamide (DMF) in water and 100 μL of 15 mg/mL nitro blue tetrazolium
dissolved in 70% DMF in water, adjusted to 50 mL with 0.1 M Tris (pH 9.5)/0.1
mM magnesium chloride.
ACKNOWLEDGMENTS. We thank Helena Wagret, James Chamberlin, Yoko
Marwidi, Hal Himmel, Iting Jaing, Ian Brown, Sean Broce, Scott Long, Connie
Ewald, Sally Hansen, and Michael Farmer for contributions to these studies.
Portions of this work were supported by grants from the Northeast Biode-
fense Consortium and from the National Institutes of Health.
1. Smith TG, Wu X, Franka R, Rupprecht CE (2011) Design of future rabies biologics and
antiviral drugs. Adv Virus Res 79:345–363.
2. Cleaveland S, Fèvre EM, Kaare M, Coleman PG (2002) Estimating human rabies
mortality in the United Republic of Tanzania from dog bite injuries. Bull World Health
Organ 80(4):304–310.
3. Deshmukh DG, Damle AS, Bajaj JK, Bhakre JB, Patil NS (2011) Fatal rabies despite post-
exposure prophylaxis. Indian J Med Microbiol 29(2):178–180.
4. Fooks AR, Rupprecht CE (2009) Rabies (Academic, Amsterdam), pp 605–627.
5. Novoa RR, et al. (2005) Virus factories: Associations of cell organelles for viral
replication and morphogenesis. Biol Cell 97(2):147–172.
6. Campbell S, Rein A (1999) In vitro assembly properties of human immunodeficiency
virus type 1 Gag protein lacking the p6 domain. J Virol 73(3):2270–2279.
7. Zlotnick A (2005) Theoretical aspects of virus capsid assembly. J Mol Recognit 18(6):479–490.
8. Dooher JE, Lingappa JR (2004) Conservation of a stepwise, energy-sensitive pathway
involving HP68 for assembly of primate lentivirus capsids in cells. J Virol 78(4):
1645–1656.
9. Dooher JE, Schneider BL, Reed JC, Lingappa JR (2007) Host ABCE1 is at plasma
membrane HIV assembly sites and its dissociation from Gag is linked to subsequent
events of virus production. Traffic 8(3):195–211.
10. Klein KC, et al. (2011) HIV Gag-leucine zipper chimeras form ABCE1-containing
intermediates and RNase-resistant immature capsids similar to those formed by wild-
type HIV-1 Gag. J Virol 85(14):7419–7435.
11. Lingappa JR, Dooher JE, Newman MA, Kiser PK, Klein KC (2006) Basic residues in the
nucleocapsid domain of Gag are required for interaction of HIV-1 gag with ABCE1
(HP68), a cellular protein important for HIV-1 capsid assembly. J Biol Chem 281(7):
3773–3784.
12. Lingappa JR, Hill RL, Wong ML, Hegde RS (1997) A multistep, ATP-dependent
pathway for assembly of human immunodeficiency virus capsids in a cell-free system.
J Cell Biol 136(3):567–581.
13. Reed JC, et al. (2012) HIV-1 Gag co-opts a cellular complex containing DDX6, a
helicase that facilitates capsid assembly. J Cell Biol 198(3):439–456.
14. Lingappa JR, et al. (1994) A eukaryotic cytosolic chaperonin is associated with a high
molecular weight intermediate in the assembly of hepatitis B virus capsid,
a multimeric particle. J Cell Biol 125(1):99–111.
15. Klein KC, Dellos SR, Lingappa JR (2005) Identification of residues in the hepatitis C
virus core protein that are critical for capsid assembly in a cell-free system. J Virol
79(11):6814–6826.
16. Klein KC, Polyak SJ, Lingappa JR (2004) Unique features of hepatitis C virus capsid
formation revealed by de novo cell-free assembly. J Virol 78(17):9257–9269.
17. Kelly BN, et al. (2007) Structure of the antiviral assembly inhibitor CAP-1 complex with
the HIV-1 CA protein. J Mol Biol 373(2):355–366.
18. Lemke CT, et al. (2012) Distinct effects of two HIV-1 capsid assembly inhibitor families
that bind the same site within the N-terminal domain of the viral CA protein. J Virol
86(12):6643–6655.
19. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1(9):
727–730.
20. Goff SP (2008) Knockdown screens to knockout HIV-1. Cell 135(3):417–420.
21. Alberts B (1998) The cell as a collection of protein machines: Preparing the next
generation of molecular biologists. Cell 92(3):291–294.
22. Fulton AB (1982) How crowded is the cytoplasm? Cell 30(2):345–347.
23. Perica T, et al. (2012) The emergence of protein complexes: Quaternary structure,
dynamics and allostery. Colworth Medal Lecture. Biochem Soc Trans 40(3):475–491.
Fig. 11. Starting PMiS glycerol gradient fractions and their column eluates
analyzed by Western blot with anti-ABCE1. Note the heterogeneity of
ABCE1 not only in the size of the immunoreactive protein species (pre-
sumably because of posttranslational modifications) but also across the
gradient as demonstrated by drug column binding being limited largely
to fraction 3. Note also that the ∼70-kDa isoform that is a minor species in
the total gradient fraction 3 (Top) is greatly enriched in the column 124 free
drug eluate (Middle). The Bottom panel is the eluate of each glycerol gra-
dient fraction applied to the control column 74 (blocked resin), demon-
strating the specificity of the ABCE1 immunoreactivity seen in fraction 3 of
the Middle panel.














24. Ozbabacan SE, Engin HB, Gursoy A, Keskin O (2011) Transient protein-protein
interactions. Protein Eng Des Sel 24(9):635–648.
25. Khan SH, Ahmad F, Ahmad N, Flynn DC, Kumar R (2011) Protein-protein interactions:
Principles, techniques, and their potential role in new drug development. J Biomol
Struct Dyn 28(6):929–938.
26. Thompson AD, Dugan A, Gestwicki JE, Mapp AK (2012) Fine-tuning multiprotein
complexes using small molecules. ACS Chem Biol 7(8):1311–1320.
27. Shimizu K, Toh H (2009) Interaction between intrinsically disordered proteins
frequently occurs in a human protein-protein interaction network. J Mol Biol 392(5):
1253–1265.
28. Blobel G (2000) Protein targeting (Nobel lecture). ChemBioChem 1(2):86–102.
29. Jayakar HR, Jeetendra E, Whitt MA (2004) Rhabdovirus assembly and budding. Virus
Res 106(2):117–132.
30. Majumder A, et al. (2001) Effect of osmolytes and chaperone-like action of P-protein
on folding of nucleocapsid protein of Chandipura virus. J Biol Chem 276(33):
30948–30955.
31. Mondal A, et al. (2012) Interaction of chandipura virus N and P proteins: Identification
of two mutually exclusive domains of N involved in interaction with P. PLoS ONE 7(4):
e34623.
32. Liu P, Yang J, Wu X, Fu ZF (2004) Interactions amongst rabies virus nucleoprotein,
phosphoprotein and genomic RNA in virus-infected and transfected cells. J Gen Virol
85(Pt 12):3725–3734.
33. Mavrakis M, et al. (2003) Isolation and characterisation of the rabies virus N degrees-P
complex produced in insect cells. Virology 305(2):406–414.
34. Wunner WH (1991) The Chemical Composition and Molecular Structure of Rabies
Viruses (Centers for Disease Control, Atlanta) pp 31–67.
35. Dooher JE, Lingappa JR (2004) Cell-free systems for capsid assembly of primate
lentiviruses from three different lineages. J Med Primatol 33(5-6):272–280.
36. Lingappa JR, Newman MA, Klein KC, Dooher JE (2005) Comparing capsid assembly of
primate lentiviruses and hepatitis B virus using cell-free systems.Virology 333(1):114–123.
37. Singh AR, Hill RL, Lingappa JR (2001) Effect of mutations in Gag on assembly of
immature human immunodeficiency virus type 1 capsids in a cell-free system. Virology
279(1):257–270.
38. Fauman EB, Rai BK, Huang ES (2011) Structure-based druggability assessment—
identifying suitable targets for small molecule therapeutics. Curr Opin Chem Biol
15(4):463–468.
39. Lee WC, Lee KH (2004) Applications of affinity chromatography in proteomics. Anal
Biochem 324(1):1–10.
40. Zimmerman C, et al. (2002) Identification of a host protein essential for assembly of
immature HIV-1 capsids. Nature 415(6867):88–92.
41. Bisbal C, Martinand C, Silhol M, Lebleu B, Salehzada T (1995) Cloning and
characterization of a RNAse L inhibitor. A new component of the interferon-
regulated 2-5A pathway. J Biol Chem 270(22):13308–13317.
42. Barthelme D, et al. (2011) Ribosome recycling depends on a mechanistic link between
the FeS cluster domain and a conformational switch of the twin-ATPase ABCE1. Proc
Natl Acad Sci USA 108(8):3228–3233.
43. Becker T, et al. (2012) Structural basis of highly conserved ribosome recycling in
eukaryotes and archaea. Nature 482(7386):501–506.
44. Khoshnevis S, et al. (2010) The iron-sulphur protein RNase L inhibitor functions in
translation termination. EMBO Rep 11(3):214–219.
45. Pisarev AV, et al. (2010) The role of ABCE1 in eukaryotic posttermination ribosomal
recycling. Mol Cell 37(2):196–210.
46. Shoemaker CJ, Green R (2011) Kinetic analysis reveals the ordered coupling of
translation termination and ribosome recycling in yeast. Proc Natl Acad Sci USA
108(51):E1392–E1398.
47. Purich DL (2001) Enzyme catalysis: A new definition accounting for noncovalent
substrate- and product-like states. Trends Biochem Sci 26(7):417–421.
48. Albertini AA, et al. (2006) Crystal structure of the rabies virus nucleoprotein-RNA
complex. Science 313(5785):360–363.
49. Harlow E, Lane D (1999) Using Antibodies: A Laboratory Manual (Cold Spring
Harbor Laboratory, Cold Spring Harbor, NY).
E868 | www.pnas.org/cgi/doi/10.1073/pnas.1210198110 Lingappa et al.
